Company / Cash & Equivalents
Insulet Corporation Cash & Equivalents History
FY2016-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$907.2M
FY2020
5-year range
-
FY2016-FY2020
Trend
+324.5%
vs FY2019
Sector context
#33 of 152
Health Care
What the data says
Cash & Equivalents changed +325% YoY in FY2020, a notable deviation from the 4-year average annual change of +113%.
Based on SEC 10-K filings.
$907M in FY2020 with a 3-year CAGR of +49.3%. Top quartile in the Health Care sector.
Improved from $114M to $907M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +49.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 22% in Health CareTop 22% of 152This company $907.2M Sector average $1.2B
▼
-22.1% below sector average
Key checks
Key Insights
- 3-year CAGR of +49.3%, indicating consistent growth.
- In FY2020, cash & equivalents increased 324.5% year-over-year.
- Ranks #33 out of 152 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2018.
Company context
Key Data Points
- Strong profit margin: 20.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | $907.2M | +324.5% |
| FY2019 | $213.7M | +87.6% |
| FY2018 | $113.9M | -58.2% |
| FY2017 | $272.6M | +98.7% |
| FY2016 | $137.2M | +11.8% |
As of FY2020 · SEC 10-K · Updated Feb 28, 2026